Komori
Earnings presentation7096StemCell InstituteInformation and Communications, Services and Others

First-Quarter Financial Results Presentation for the Fiscal Year Ending March 2027

In Q1 of the fiscal year ending March 2027, domestic revenue and operating profit exceeded the year-earlier period, while overseas operations recorded an operating loss due to upfront investment related to preparations to commence operations in Singapore. The full-year earnings forecast remains unchanged from the figures announced on 13 May 2026.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
41
% (year-on-year change in domestic operating profit)
Wording
Conditional
How definitive the wording is.

Contents of this document

Earnings presentationFirst quarter of the fiscal year ending March 20274 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales722 million yen
Operating profit40 million yen
Ordinary income43 million yen
Net income35 million yen
Gross Profit Margin58.6
Operating profit margin5.7
Selling, general and administrative expenses382 million yen
Results for the three months of the current quarter
Net Sales
722 million yen
Operating profit
40 million yen
Ordinary income
43 million yen
Profit attributable to owners of parent for the quarter
35 million yen
Full-year earnings forecast
Net Sales
3,100 million yen
Operating profit
100 million yen
Domestic revenue
3,000 million yen
Overseas revenue
100 million yen
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales
Progress toward full-year plan23.3 %
Q1 basis25 %
Operating profit
Progress toward full-year plan41 %
Q1 basis25 %
What the company explained in this material
New initiatives
  • Continuation of the campaign offering five years of storage fees free of charge
  • Expansion of lump-sum payment discounts and fee-free installment payments of up to 120 installments
  • Strengthening cooperation with obstetric facilities and restructuring the sales organization
  • Expansion of Family Supernatant® into the nerve regeneration field
  • Development of a cell processing center and cell storage center in Singapore
  • Negotiations with local partners for expansion into Indonesia and Vietnam
Key KPIsA metric the company considers important as a management benchmark.
  • Stored specimens (total)3,212 Engagements
    Year on year against the same period last year+2.8%
  • Umbilical cord blood specimens stored1,882 Engagements
    Year on year against the same period last year+2.1%
  • Umbilical cord specimens stored1,330 Engagements
    Year on year against the same period last year+3.9%
  • HOPECELL information requests2,385 Engagements
  • Number of expectant mothers due to give birth each month under HOPECELL2,320 people
  • HOPECELL conversion rate29 %
Segment results
Domestic
Net Sales
722 million yen+3.0%
Operating profit
92 million yen+41.0%
Overseas expansion
Operating profit
-51 million yen
Medium-term management plan targets
Target fiscal yearFiscal year ending March 2030
Net Sales
5,500 million yen
Operating profit
1,000 million yen
Operating profit margin
18.2 %
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredFirst quarter of the fiscal year ending March 2027
Net Sales722 million yen
Operating profit40 million yen
Ordinary income43 million yen
Net income35 million yen
Gross Profit Margin58.6
Operating profit margin5.7
Selling, general and administrative expenses382 million yen
Results for the three months of the current quarterNet Sales 722 million yen / Operating profit 40 million yen / Ordinary income 43 million yen / Profit attributable to owners of parent for the quarter 35 million yen
Full-year earnings forecastNet Sales 3,100 million yen / Operating profit 100 million yen / Domestic revenue 3,000 million yen / Overseas revenue 100 million yen
Progress against full-year forecastNet Sales Progress toward full-year plan 23.3 % / Q1 basis 25 % / Operating profit Progress toward full-year plan 41 % / Q1 basis 25 %
Segment resultsDomestic Net Sales 722 million yen (YoY +3.0%) / Operating profit 92 million yen (YoY +41.0%) / Overseas expansion Net Sales Not disclosed / Operating profit -51 million yen
Key KPIsIndicator name Stored specimens (total) / Value 3,212 Engagements / Year on year against the same period last year 2.8 Engagements, Indicator name Umbilical cord blood specimens stored / Value 1,882 Engagements / Year on year against the same period last year 2.1 Engagements, Indicator name Umbilical cord specimens stored / Value 1,330 Engagements / Year on year against the same period last year 3.9 Engagements, Indicator name HOPECELL information requests / Value 2,385 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of expectant mothers due to give birth each month under HOPECELL / Value 2,320 people / Year on year against the same period last year Not disclosed, Indicator name HOPECELL conversion rate / Value 29 % / Year on year against the same period last year Not disclosed
Medium-term management plan targetsTarget fiscal year Fiscal year ending March 2030 / Net Sales 5,500 million yen / Operating profit 1,000 million yen / Operating profit margin 18.2 %
New initiativesContinuation of the campaign offering five years of storage fees free of charge, Expansion of lump-sum payment discounts and fee-free installment payments of up to 120 installments, Strengthening cooperation with obstetric facilities and restructuring the sales organization, Expansion of Family Supernatant® into the nerve regeneration field, Development of a cell processing center and cell storage center in Singapore, Negotiations with local partners for expansion into Indonesia and Vietnam
Items this document does not state (15)
Self-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In Japan, the company continued its free storage fee campaign, promoted the new HOPECELL plan, expanded discounts for lump-sum payments, and strengthened cooperation with obstetric facilities. Overseas, it continued upfront investment to prepare personnel, business workflows and the operating structure for the launch of operations in Singapore. The launch timing was revised from the initial target of June 2026 to around September 2026 because confirming and responding to administrative procedures took longer than expected. However, fluctuations in the timing of obtaining the license have already been incorporated into the plan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
First-Quarter Financial Results Presentation for the Fiscal Year Ending March 2027 | StemCell Institute (7096) timely disclosure | Komori